BIRC5 and acute myeloid leukemia: Consistent with this hypothesis, analysis of previously described group of 260 adult AML patients with diverse cytogenetic and molecular abnormalities36 revealed that a dichotomous stratification of patients into low MUC1 and high MUC1 expression groups was associated with a significantly decreased risk of death in the low expressing group (P = .04) as demonstrated in Figure 7A. Similarly, association of survivin (BIRC5) expression and clinical outcomes was assessed.